K. Altundag

发表

Differential alteration of drug metabolizing enzyme activities after cyclophosphamide/adriamycin administration in breast cancer patients

T. Elkıran, H. Harputluoglu, U. Yasar, 2007, Methods and findings in experimental and clinical pharmacology.

From endometrial hyperplasia to endometrial cancer: insight into the biology and possible medical preventive measures

K. Altundag, M. C. Boruban, G. Kilic, 2008, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

Effect of body mass index on the efficacy of adjuvant tamoxifen in premenopausal patients with hormone receptor-positive breast cancer.

K. Altundag, O. Yazıcı, N. Zengi̇n, 2016, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

Metastatic occult breast carcinoma to gallbladder initially presenting as acute cholecystitis.

K. Altundag, K. Altundağ, 2021, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

A systemic late recurrence after the first operation in a patient diagnosed with early-stage breast cancer: the latest recurrence in the literature.

K. Altundag, Z. Arık, T. Babacan, 2015, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

Comparative efficacy study of 5-year letrozole or anastrozole in postmenopausal hormone receptor-positive early breast cancer.

K. Altundag, N. Zengi̇n, S. Aksoy, 2013, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

The role of aromatase inhibitors in the adjuvant treatment of breast carcinoma

G. Hortobagyi, R. Theriault, A. Buzdar, 2004, Cancer.

Does letrozole have any place in adjuvant setting in breast cancer patients with documented hypercoagulability?

K. Altundag, Y. Ozisik, B. Oyan, 2004, American journal of clinical oncology.

The field of radiation therapy may effect health-related quality of life in patients with operable breast cancer.

K. Altundag, O. Altundag, M. Cengiz, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Patients’ understanding of treatment goals and disease course and their relationship with optimism, hope, and quality of life: a preliminary study among advanced breast cancer outpatients before receiving palliative treatment

K. Altundag, A. Sever, T. Babacan, 2016, Supportive Care in Cancer.

Radio-sensitising effect of T-DM1 should not be discarded for the efficacy of radiosurgery in the management of brain metastases in patients with HER2-positive metastatic breast cancer

K. Altundag, 2017, Journal of Neuro-Oncology.

Free circulating DNA: good as a diagnostic marker in lung cancer?

K. Altundag, O. Altundag, M. Altundağ, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effects of tamoxifen on urinary incontinence

E. Jonasch, K. Altundag, R. Hasanov, 2017, Medicine.

Comparative study of receptor discordance between primary and corresponding metastatic lesions in breast cancer.

K. Altundag, Y. Bozkaya, N. Zengi̇n, 2017, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

Management of hair loss associated with endocrine therapy in patients with breast cancer: an overview

K. Altundag, A. Sever, S. Şahin, 2016, SpringerPlus.

Acute promyelocytic leukemia in a young patient with breast cancer

K. Altundag, O. Kara, E. Ozdemir, 2011, Medical oncology.

Comparative study of the immunohistochemical detection of hormone receptor status and HER-2 expression in primary and paired recurrent/metastatic lesions of patients with breast cancer

K. Altundag, Y. Ozisik, G. Guler, 2011, Medical oncology.

Angiotensin 1–7 and risk for breast cancer recurrence

K. Altundag, O. Altundag, K. Silay, 2006, Cancer Chemotherapy and Pharmacology.

A Phase II Study on the Safety and Efficacy of 5-Fluorouracil, Epirubicin, Cyclophosphamide (FEC) Followed by Paclitaxel in the Adjuvant Treatment of Breast Cancer

K. Altundag, Y. Ozisik, N. Guler, 2005, Cancer investigation.

Propylthiouracil may play a role in the pathogenesis of thyroid lymphoma

K. Altundag, T. Purnak, A. Y. Savaş, 2009 .

Angiotensin-Converting Enzyme Inhibitors for Bevacizumab-Induced Hypertension

K. Altundag, M. Dinçer, K. Altundağ, 2006, The Annals of pharmacotherapy.

Cyclooxygenase inhibitors may be more effective in hormone-dependent endometrial cancers: interaction between cyclooxygenase and aromatase.

K. Altundag, P. Morandi, O. Altundag, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Is it feasible to adjust bisphosphonate dose according to bone mineral density value in postmenopausal breast cancer patients with bone metastases?

K. Altundag, T. Delibaşı, O. Altundag, 2006, Medical hypotheses.

Association between family history and clinicopathologic characteristics in 1987 breast cancer patients: single institution experience from Turkey.

K. Altundag, Y. Ozisik, Z. Arık, 2012, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

Evaluation of changes in biologic markers ER, PR, HER 2 and Ki-67 index in breast cancer with administration of neoadjuvant dose dense doxorubicin, cyclophosphamide followed by paclitaxel chemotherapy.

K. Altundag, Y. Ozisik, G. Guler, 2013, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

Evaluation of changes of biologic markers ER, PR, HER 2 and Ki-67 in breast cancer with administration of neoadjuvant dose-dense doxorubicin, cyclophosphamide followed by paclitaxel.

K. Altundag, Y. Ozisik, G. Guler, 2013, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

Handedness and breast cancer characteristics.

K. Altundag, A. Sever, M. Işık, 2016, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

Coincidence of increased pulmonary artery pressure and patent septum foramen ovale in patients with solid tumors may have a propensity to develop central nervous system metastases.

H. Harputluoglu, K. Altundag, O. Dizdar, 2006, Medical hypotheses.

Regular exercise might be associated with higher skeletal muscle volume, favorable prognostic factor in breast cancer patients

K. Altundag, 2018, Breast Cancer Research and Treatment.

Human papilloma virus and breast cancer. Authors' replay

K. Altundag, J. Lawson, N. Whitaker, 2006 .

Human papilloma virus and breast cancer

K. Altundag, M. Baptista, 2005, British Journal of Cancer.

Possible interaction between activator protein-1 and proto-oncogene B-cell lymphoma gene 6 in breast cancer patients resistant to tamoxifen.

K. Altundag, B. Arun, M. Gunduz, 2004, Medical hypotheses.

The effect of obesity on recurrence pattern in early breast cancer patients.

K. Altundag, Y. Ozisik, O. Yazıcı, 2015, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

The prognostic impact of obesity on molecular subtypes of breast cancer in premenopausal women.

K. Altundag, Y. Ozisik, Z. Arık, 2013, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

Calcium and vitamin D supplementation during bisphosphonate administration may increase osteoclastic activity in patients with bone metastasis.

K. Altundag, M. Gunduz, O. Altundag, 2004, Medical hypotheses.

Impact of the obesity on lymph node status in operable breast cancer patients.

K. Altundag, Z. Arık, E. Esin, 2013, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

Do multifocal or multicentric pT1a node-negative HER2+ breast cancers get benefit from systemic treatment?

K. Altundag, 2019, Breast Cancer Research and Treatment.

Reproductive and hormonal risk factors for postmenopausal luminal, HER‐2‐overexpressing, and triple‐negative breast cancer

K. Altundag, O. Dizdar, S. Aksoy, 2009, Cancer.

Association between androgen receptor status and prognosis in triple negative breast cancer.

K. Altundag, S. Aksoy, F. Sarici, 2018, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

Correlation of educational status and clinicopathological characteristics of breast cancer: a single center experience.

K. Altundag, O. Unlu, A. Sever, 2015, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

Triple-negative breast cancer and brain metastases.

K. Altundag, E. Çinar, B. Sait, 2010, Clinical oncology (Royal College of Radiologists (Great Britain)).

Cetuximab-induced esophageal ulcer: the first report in literature

K. Altundag, T. Babacan, I. Turkbeyler, 2014, The Libyan journal of medicine.

Chemotherapy and biological treatment options in breast cancer patients with brain metastasis: an update

K. Altundag, O. Dizdar, Ç. Arslan, 2014, Expert opinion on pharmacotherapy.

Evaluating The Clinicopathologic Characteristics and Survival Outcome of Breast Cancer Patients with Isolated Brain Metastases after Adjuvant Treatment or at Initial Diagnosis

K. Altundag, M. Cengiz, M. Artaç, 2012 .

Obesity may be a independent prognostic factor in premenopausal breast cancer patients.

K. Altundag, P. Morandi, M. Gunduz, 2004, Breast.

Bisphosphonate-Related Osteonecrosis and Metastasis Within the Same Site of the Jaw: Expected for Multiple Myeloma, But Unusual for Breast Cancer.

K. Altundag, 2017, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

Demographic and clinico-pathological characteristics of breast cancer patients with history of oral alendronate use

K. Altundag, Z. Arık, N. Zengi̇n, 2012, Medical Oncology.

Ductal Carcinoma in Situ and Bilateral Atypical Ductal Hyperplasia in a 23-Year-Old Man with Gynecomastia

K. Altundag, G. Gunaydin, K. Altundağ, 2011, The American surgeon.

Acidosis might make breast cancer cells more susceptible to metastasize by shifting CXCL12 monomer-dimer equilibrium to monomeric state.

K. Altundag, O. Altundag, C. Boruban, 2005, Medical hypotheses.

Favorable results of patients with pT1a, b, c, lymph node-negative early breast cancer in the long interval

K. Altundag, A. Ulaş, N. Bulut, 2019, Journal of cancer research and therapeutics.

Metaplastic breast carcinoma: a heterogeneous disease.

K. Altundag, Y. Ozisik, N. Guler, 2014, Asian Pacific journal of cancer prevention : APJCP.

Does Androgen Receptor Have a Prognostic Role in Patients with Estrogen/Progesterone-Negative and c-erbB-2-Positive Breast Cancer?

K. Altundag, Y. Ozisik, G. Guler, 2012, The American surgeon.

Imatinib mesylate lacks activity in small cell lung carcinoma expressing c‐kit protein: A phase II clinical trial

K. Altundag, O. Altundag, C. Boruban, 2005, Cancer.

Salvage ifosfamide-doxorubicin chemotherapy in patients with recurrent nasopharyngeal carcinoma pretreated with cisplatin-based chemotherapy

K. Altundag, E. Ozyar, O. Altundag, 2004, Medical oncology.

Treatment of advanced soft tissue sarcomas with ifosfamide and doxorubicin combination chemotherapy

K. Altundag, N. Zengi̇n, N. Güler, 2000, Journal of surgical oncology.

Comparison of prognosis and clinical features between synchronous bilateral and unilateral breast cancers.

K. Altundag, S. Aksoy, N. Kertmen, 2017, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

Adjuvant targeted therapy with trastuzumab may decrease metastatic capacity in specific group of oropharyngeal cancer patients: downregulation of E-cadherin-catenin complex by cooperative effect of erbB-2 and human papillomavirus type 16 E6/E7 protooncogenes.

K. Altundag, P. Morandi, M. Gunduz, 2004, Medical hypotheses.

Phenytoin may increase the efficacy of temozolomide by methylating DNA-repair enzyme, O6-methylguanine-DNA methyltransferase in patients with glioblastoma.

K. Altundag, O. Altundag, C. Boruban, 2005, Medical hypotheses.

Association between epidermal growth factor receptor mutation and improved survival in never-smokers with primary adenocarcinoma of the lung.

K. Altundag, P. Morandi, M. Gunduz, 2005, Chest.

HER2/neu intragenic kinase domain mutations may be major determinant of response to trastuzumab or specific kinase inhibitors in non-small cell lung cancer patients.

K. Altundag, O. Altundag, Y. Silay, 2005, Lung cancer.

Activation patterns of epidermal growth factor-receptor signaling in glioblastoma multiforme: in regard to Chakravarti et al. (Int J Radiat Oncol Biol Phys 2005;62:318-327).

K. Altundag, O. Altundag, E. Gunduz, 2005, International journal of radiation oncology, biology, physics.

Targeted therapy for targeted patients: trastuzumab in adjuvant treatment of non-small-cell lung cancer.

K. Altundag, P. Morandi, M. Gunduz, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Addition of granulocyte-colony stimulating factor (G-CSF) to adjuvant treatment may increase survival in patients with operable breast cancer: interaction of G-CSF with dormant micrometastatic breast cancer cells.

K. Altundag, Y. Ozisik, O. Altundag, 2004, Medical hypotheses.

Re: Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer.

K. Altundag, Y. Ozisik, M. Gunduz, 2004, Journal of the National Cancer Institute.

Imatinib may be useful in the management of patients with glioblastoma.

K. Altundag, O. Altundag, C. Boruban, 2005, Medical hypotheses.

Receptor conversion in breast cancer patients with liver metastases after hepatectomy might affect survival

K. Altundag, K. Altundağ, 2018, Breast cancer research and treatment.

PO-0699: Impact of locoregional treatment on survival in patients presented with metastatic breast carcinoma

K. Altundag, Y. Ozisik, N. Guler, 2014 .

Impact of locoregional treatment on survival in patients presented with metastatic breast carcinoma.

K. Altundag, Y. Ozisik, N. Guler, 2014, Breast.

Adjuvant chemotherapy in patients 80-89 years of age with non-small cell lung cancer.

K. Altundag, Mustafa A. Atik, O. Altundag, 2005, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

Possible association between Budd‐Chiari syndrome and gemtuzumab ozogamicin treatment in a patient with refractory acute myelogenous leukemia

K. Altundag, E. Kansu, M. Kurt, 2005, American journal of hematology.

Frequency and Risk Factors Associated With Osteonecrosis of the Jaw in Cancer Patients Treated With Intravenous Bisphosphonates

G. Hortobagyi, K. Altundag, C. Warneke, 2008, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

A comprehensive review of denosumab for bone metastasis in patients with solid tumors

K. Altundag, A. Sever, S. Aksoy, 2016, Current medical research and opinion.

Association between Tumor Characteristics and Bone Mineral Density in Postmenopausal Breast Cancer Patients

K. Altundag, B. Arun, K. Broglio, 2013, The breast journal.

The role of zoledronic acid in the adjuvant treatment of breast cancer: current perspectives

K. Altundag, Ç. Arslan, O. Tonyali, 2010, Expert opinion on pharmacotherapy.

Molecular subtypes might affect chemotherapy-induced peripheral neuropathy in breast cancer patients receiving neoadjuvant chemotherapy.

K. Altundag, 2018, Journal of psychosomatic research.

Increased pathologic complete response are expected in HER2-positive and triple-negative locally advanced breast cancers

K. Altundag, K. Altundağ, 2017, Chinese journal of cancer.

Sequential taxane and anthracycline-containing neo-adjuvant regimens; any rationale behind the sequence?

K. Altundag, I. Sahin, E. Ararat, 2011, Breast.

Potential molecular targeted therapies in the management of the basal-like subtype of breast cancer.

H. Harputluoglu, K. Altundag, M. Kurt, 2007, Breast.

Albumin-bound paclitaxel (ABI-007; Abraxane) in the management of basal-like breast carcinoma

K. Altundag, T. Purnak, D. Dede, 2006, Journal of Clinical Pathology.

Albumin-Bound Paclitaxel, ABI-007 May Show Better Efficacy than Paclitaxel in Basal-Like Breast Cancers: Association Between Caveolin-1 Expression and ABI-007

H. Harputluoglu, K. Altundag, O. Dizdar, 2006, Breast Cancer Research and Treatment.

Medullary carcinoma of the breast: a brief report from a tertiary care center.

K. Altundag, M. C. Kızılarslanoğlu, E. Roach, 2012, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

Pamidronate, hypocalcemia, and calcium and vitamin D supplementation.

K. Altundag, O. Altundag, K. Altundağ, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comment to “Patients with Concordant Triple-Negative Phenotype between Primary Breast Cancers and Corresponding Metastases Have Poor Prognosis”

K. Altundag, K. Altundağ, 2016, Journal of breast cancer.

Estrogen receptor immunohistochemistry cutoff value: standardization is needed.

K. Altundag, O. Dizdar, Ç. Arslan, 2010, Human pathology.

Phase II Study of Loading-Dose Ibandronate Treatment in Patients with Breast Cancer and Bone Metastases Suffering from Moderate to Severe Pain

K. Altundag, O. Dizdar, Z. Ozsaran, 2012, Oncology Research and Treatment.

Zoledronic Acid A Review of its Use in Breast Cancer

K. Altundag, Wolters Kluwer, A. Evaluation, 2008 .

Adjuvant use of epidermal growth factor receptor kinase inhibitors may prevent bone metastases in patients with non-small cell lung carcinoma.

H. Harputluoglu, K. Altundag, O. Dizdar, 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Prognostic role of inflammatory biomarkers in metastatic breast cancer.

K. Altundag, O. Unlu, E. Petekkaya, 2017, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

Impact of inflammatory markers on the prognosis of patients with operable breast cancer.

K. Altundag, E. Petekkaya, A. Okoh, 2014, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

Serum levels of CEA and CA 15-3 in triple-negative breast cancer at the time of diagnosis

K. Altundag, Ç. Arslan, D. Dede, 2010, Medical oncology.

Imatinib mesylate and zoledronic acid in androgen-independent prostate cancer.

K. Altundag, P. Morandi, M. Gunduz, 2005, Urology.

Multiple myeloma [6] (multiple letters)

K. Altundag, R. Kyle, S. Rajkumar, 2005 .

Leptin and breast cancer: an overview

K. Altundag, M. Artaç, K. Altundağ, 2012, Medical Oncology.